Congratulations to Atsena Therapeutics on their positive clinical data from the first cohort of their ongoing LIGHTHOUSE study, a Phase I/II trial evaluating subretinal injection of ATSN-201, a gene therapy for the treatment of X-linked retinoschisis (XLRS). Looking forward to future updates! Full press release: https://bit.ly/44skKq3
We are excited to share data from the first cohort of the LIGHTHOUSE study, our ongoing Phase I/II clinical trial evaluating our investigational #GeneTherapy ATSN-201 for the treatment of X-linked retinoschisis (#XLRS). For the first time in patients, we have validated the ability of AAV.SPR, our novel spreading #capsid, to spread laterally well beyond the subretinal injection blebs. Additionally, we have demonstrated the ability to safely administer subretinal injections in patients with extensive retinal schisis. Subretinal injection of ATSN-201 was well tolerated in all three patients in the first cohort with two patients showing extensive resolution of schisis beginning at 8 weeks after dosing. Additional and continued resolution of schisis was observed through week 24, the latest time point available. Read more about the data in our press release: https://lnkd.in/eAcpdUHS